The study will evaluate the drug in menopause related vasomotor symptoms, such as hot flashes and night sweats. More: First patient dosed in Astellas’ late-stage menopause trial Source: News
read moreFatigue is one of the most common side effects of cancer and its treatment, with 70-80% of patients affected. More: NHS approves app for cancer related fatigue Source: News
read moreThe treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate. More: Trial success for Lynparza in prostate cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals